All In Biotech

Drug Trial Radar · NCT00653224

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis

Last checked: Nov 20, 2026Latest source record: Aug 31, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 580 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

580

Actual

Start

Apr 2008

Primary completion

Jul 2008

Study completion Jul 2008

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Apr 4, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study objective is to investigate the efficacy of levocetirizine in reducing symptoms associated with seasonal allergic rhinitis and in improving rhinitis-related Quality of Life.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • levocetirizine dihydrochlorideDrug

    5 mg daily (oral tablet) for 14 days

  • placeboDrug

    0 mg daily (matching oral tablet) for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean 24-hour Reflective Total 5 Symptoms Score (T5SS) Over the Total Treatment Period (14 Days)Time frame: Over the total treatment period (14 days)

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Tucson, Arizona

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    San Francisco, California

  • Site not named

    San Jose, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Miami, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Gainesville, Georgia

  • Site not named

    Lawrenceville, Georgia

  • Site not named

    Stockbridge, Georgia

  • Site not named

    Normal, Illinois

  • Site not named

    Louisville, Kentucky

  • Site not named

    Harvard, Massachusetts

  • Site not named

    North Dartmouth, Massachusetts

  • Site not named

    Novi, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Berlin, New Jersey

  • Site not named

    Skillman, New Jersey

  • Site not named

    Verona, New Jersey

  • Site not named

    Rochester, New York

  • Site not named

    Asheville, North Carolina

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Wilmington, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Edmond, Oklahoma

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Portland, Oregon

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Upland, Pennsylvania

  • Site not named

    Lincoln, Rhode Island

  • Site not named

    Germantown, Tennessee

  • Site not named

    San Antonio, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    South Burlington, Vermont

  • Site not named

    Arlington, Virginia

  • Site not named

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.